---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-025196"
form_type: "8-K"
ticker: "BCYC"
cik: "0001761612"
company_name: "BICYCLE THERAPEUTICS PLC"
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T23:16:17.493351+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bicycle Therapeutics Q4 net loss $49.1M; cash $526.4M; BT8009 Phase 2/3 trial recruiting

## Summary
- Net loss $49.1M ($1.16/share) in Q4 2023 vs $30.0M prior year; full year loss $180.7M ($5.08).
- Cash $526.4M as of Dec 31, 2023, up from $339.2M; financial runway expected into 2026.
- BT8009 Phase 2/3 Duravelo-2 registrational trial for metastatic urothelial cancer now active and recruiting.
- BT8009 showed 38% objective response rate in EV-naïve mUC patients; differentiated safety profile.
- Stephen Sands appointed to Board; former chairman of Lazard's Global Healthcare Group, serves on Audit and Strategic Committees.

## SEC filing metadata
- accession: 0001104659-24-025196
- form_type: 8-K
- ticker: BCYC
- cik: 0001761612
- company_name: BICYCLE THERAPEUTICS PLC
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761612/000110465924025196/0001104659-24-025196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761612/000110465924025196/tm246555d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-025196
- JSON: https://secwatch.observer/filing/0001104659-24-025196.json
- Plain text: https://secwatch.observer/filing/0001104659-24-025196.txt

## Key facts
- Earnings Releases
  BICYCLE THERAPEUTICS PLC reported financial results for the fiscal quarter and the year ended December 31, 2023.
  - Period: the fiscal quarter and the year ended December 31, 2023
  - Result: reported results
  source text: On February 20, 2024, Bicycle Therapeutics plc (the “Company”) issued a press release announcing financial results for the fiscal quarter and the year ended December 31, 2023 and other business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761612/000110465924025196/0001104659-24-025196-index.htm
- Executive change
  Stephen Sands was appointed as Director at BICYCLE THERAPEUTICS PLC.
  - Action: appointed
  - Role: Director
  source text: On February 20, 2024, the Board of Directors (the “Board”) of the Company, upon the recommendation of the Nominating & Corporate Governance Committee of the Board, appointed Stephen Sands to the Board, effective as of the close of business on February 20, 2024, New York City time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761612/000110465924025196/0001104659-24-025196-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.